Advertisement
UK markets close in 26 minutes
  • FTSE 100

    7,964.77
    +32.79 (+0.41%)
     
  • FTSE 250

    19,891.48
    +80.82 (+0.41%)
     
  • AIM

    743.68
    +1.57 (+0.21%)
     
  • GBP/EUR

    1.1697
    +0.0028 (+0.24%)
     
  • GBP/USD

    1.2632
    -0.0006 (-0.04%)
     
  • Bitcoin GBP

    56,444.11
    +1,766.50 (+3.23%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,253.64
    +5.15 (+0.10%)
     
  • DOW

    39,784.22
    +24.14 (+0.06%)
     
  • CRUDE OIL

    82.69
    +1.34 (+1.65%)
     
  • GOLD FUTURES

    2,235.10
    +22.40 (+1.01%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,497.59
    +20.50 (+0.11%)
     
  • CAC 40

    8,211.50
    +6.69 (+0.08%)
     

Insights on the COVID-19 Testing Global Market 2022 - AI Mines CT, Lab Results to Predict COVID-19 Severity

Company Logo
Company Logo

Dublin, May 12, 2022 (GLOBE NEWSWIRE) -- The "COVID-19 Testing Market Update, 2022" report has been added to ResearchAndMarkets.com's offering.

This report, COVID-19 Testing Market Update, 2022, provides market sizing and estimates for COVID-19 tests with some discussion of market impacts of COVID-19. The scourge of COVID-19 continued to occupy laboratories and the in vitro diagnostic (IVD) companies that serve them throughout 2021 and into 2022. Testing already present in large labs and clinics entered the home last year, which added to market revenues.

At the time of publication, there is a slight decrease in cases which might suggest a decrease in COVID-19 testing revenues, but we've been through this before. Predicting COVID-19 is not easy. For the past two years, the disease has confounded prediction. There are at least two schools of thought about 2022. One is that COVID, as a result of the highly contagious Omicron and Delta variants, exposed enough of the population to have antibodies, and this along with strong vaccination rates and boostering, makes COVID-19 a still present but waning disease. Even in this optimistic scenario, testing will be at high volume and remains necessary throughout 2022, but there would be a decline in revenues.

A more pessimistic disease scenario would be that there are other variants that prove to be contagious, and vaccines do not provide enough long term protection and the population isn't boostering at high levels. This would represent another wave like that seen during Q4 2021 and might suggest that such waves will be with us for some time. The second scenario obviously would create COVID-19 testing revenues and volumes higher than 2021.

Key Topics Covered:

Chapter 1: Executive Summary

  • COVID-19 Testing Market Demand and Growth

  • Growth Outlook

  • Country Distribution

  • Test Innovations and Approvals

Chapter 2: Trends and Developments

  • Antigen and Molecular Product Developments

  • Antigen

  • Molecular

  • Other Developments

  • COVID-19 Testing Expands Multiplex Testing

  • COVID-19 Drives Molecular Point of Care Growth

  • AI Mines CT, Lab Results to Predict COVID-19 Severity

  • Long COVID Can Be Predicted Early On

  • Spectroscopy Employed in COVID-19

ADVERTISEMENT

Chapter 3: Market Analysis COVID Testing

  • Market Analysis: Molecular, Antigen, Antibody and Rapid Tests

  • COVID-19 Test Market Share

  • COVID-19 Test Market by Country

  • US, Canada, Japan, Africa / Middle East, Rest of World)

Chapter 4: Top IVD Market Participants

  • Abbott Laboratories

  • Becton Dickinson

  • bioMerieux SA

  • Danaher Corporation

  • Hologic, Inc.

  • Qiagen

  • Genomics/NGS, Other), Q3 2021 ($ millions)

  • Quidel Corporation

  • Roche Diagnostics

  • Siemens Healthineers

  • Thermo Fisher Scientific

  • COVID-19 Test Providers

For more information about this report visit https://www.researchandmarkets.com/r/xg2gp0

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900